Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor | Journal of Medicinal Chemistry
Frontiers | The Kappa Opioid Receptor: From Addiction to Depression, and Back
Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation | Scientific Reports
Innovation – Cara Therapeutics
Pharmaceuticals | Free Full-Text | Therapeutic Potential of Kappa Opioid Agonists | HTML
Characterization of Pyrrolidinyl-hexahydro-pyranopiperazines as a Novel Kappa Opioid Receptor Agonist Scaffold | ACS Chemical Neuroscience
Opioids in cancer: The κ‑opioid receptor (Review)
Nalfurafine, a G-Protein–Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics | Hypertension
Effects of the kappa opioid receptor agonist nalfurafine on IFN-γ⁺CD4⁺... | Download Scientific Diagram
Mixed Kappa/Mu Partial Opioid Agonists as Potential Treatments for Cocaine Dependence - ScienceDirect
Untangling the complexity of opioid receptor function | Neuropsychopharmacology
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
Figure 2 from Development of κ opioid receptor antagonists. | Semantic Scholar
Frontiers | The Kappa Opioid Receptor: From Addiction to Depression, and Back
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects